DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 17, 2014--
plc (NYSE: COV) today announced that the U.S. District Court for the
District of Connecticut has granted a preliminary injunction against
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company. This injunction
results from a lawsuit filed by Covidien in June 2014 that alleges
Ethicon’s latest ultrasonic surgical product, the Harmonic ACE®+7,
infringes three Covidien patents. The injunction prevents Ethicon from
manufacturing, marketing and selling the Harmonic ACE®+7.
“Covidien operates within a highly competitive global health care
environment. We are pleased that the court has recognized the value of
our intellectual property. As demonstrated by our actions, we will
vigorously protect our innovative products, solutions and intellectual
property,” said Chris Barry, president, Advanced Surgical, Covidien.
The June 2014 lawsuit contends that U.S. Patents 6,063,050; 6,468,286;
and 6,682,544 are infringed by Ethicon’s Harmonic ACE®+7 Shears.
Ethicon’s Harmonic® devices were found to infringe the same patents in a
prior suit in the same court that resulted in a damages award against
Ethicon of more than $175 million, a finding that is currently under
Covidien is a global health care leader that understands the challenges
faced by providers and their patients and works to address them with
innovative medical technology solutions and patient care products.
Inspired by patients and caregivers, Covidien’s team of dedicated
professionals is privileged to help save and improve lives around the
world. With more than 38,000 employees, Covidien operates in 150-plus
countries and had 2013 revenue of $10.2 billion. To learn more about our
business visit www.covidien.com
or connect with us on Twitter.
Source: Covidien plc
Marguerite Copel, 203-821-4720
Director, External Communications
Lannum, CFA, 508-452-4343